Tetratherix (TTX) Stock Overview
Engages in biomaterial and regenerative medicine business in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Tetratherix Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.96 |
| 52 Week High | AU$5.80 |
| 52 Week Low | AU$2.88 |
| Beta | 0 |
| 1 Month Change | -11.43% |
| 3 Month Change | 45.88% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 64.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| TTX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 5.5% | -0.7% | 0.3% |
| 1Y | n/a | -39.9% | 14.9% |
Return vs Industry: Insufficient data to determine how TTX performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how TTX performed against the Australian Market.
Price Volatility
| TTX volatility | |
|---|---|
| TTX Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in AU Market | 17.8% |
| 10% least volatile stocks in AU Market | 4.5% |
Stable Share Price: TTX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: TTX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 15 | Will Knox | tetratherix.com |
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.
Tetratherix Limited Fundamentals Summary
| TTX fundamental statistics | |
|---|---|
| Market cap | AU$251.80m |
| Earnings (TTM) | -AU$11.97m |
| Revenue (TTM) | AU$2.00m |
Is TTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTX income statement (TTM) | |
|---|---|
| Revenue | AU$2.00m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.00m |
| Other Expenses | AU$13.96m |
| Earnings | -AU$11.97m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -598.96% |
| Debt/Equity Ratio | 7.7% |
How did TTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 17:18 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tetratherix Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Scott Power | Morgans Financial Limited |